Neurotech International Limited (ASX:NTI) has commenced a Phase I/II open label clinical study in 20 children aged between 5-17 years with Autism Spectrum Disorder (ASD).
This much-anticipated study is being conducted under the guidance and supervision of A/Professor Michael Fahey, Head of Paediatric Neurology Monash Children’s Hospital.
It will be the first time full-spectrum <0.3% THC medicinal cannabis strains will be assessed in ASD, and NTI/DOLCE lead strain (FEN 164) will assess key behaviours in ASD over 16 weeks including a 4-week washout period (no treatment).
Neurotech’s progress in this area hasn’t gone unnoticed over the last 12 months with the company’s shares up 700% over that period.
However, a slight retracement in April may just have thrown up a useful entry point for investors looking to…